The Costs and Consequences of Methicillin-Resistant Staphylococcus aureus Infection Treatments in Canada

Andrew J Rosner; Debbie L Becker; Angelina H Wong; Elizabeth Miller; John M Conly

doi:10.1155/2004/383461

Canadian Journal of Infectious Diseases and Medical Microbiology (Jan 2004)

The Costs and Consequences of Methicillin-Resistant Staphylococcus aureus Infection Treatments in Canada

Andrew J Rosner,
Debbie L Becker,
Angelina H Wong,
Elizabeth Miller,
John M Conly

Affiliations

Andrew J Rosner: Health Economics and Outcomes Research, Innovus Research Inc, Burlington, Ontario, Canada
Debbie L Becker: Health Economics and Outcomes Research, Innovus Research Inc, Burlington, Ontario, Canada
Angelina H Wong: Patient Access and Outcomes Research, Pharmacia Canada, Mississauga, Ontario, Canada
Elizabeth Miller: Patient Access and Outcomes Research, Pharmacia Canada, Mississauga, Ontario, Canada
John M Conly: Division of Infectious Diseases, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada

DOI: https://doi.org/10.1155/2004/383461
Journal volume & issue: Vol. 15, no. 4
pp. 213 – 220

Abstract

Read online

BACKGROUND: A multinational randomized controlled trial has shown a trend toward early discharge of patients taking oral linezolid versus intravenous vancomycin (IV) in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Infection treatments resulting in shorter hospitalization durations are associated with cost savings from the hospital perspective.

Published in Canadian Journal of Infectious Diseases and Medical Microbiology

ISSN: 1712-9532 (Print); 1918-1493 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases; Science: Microbiology
Website: https://onlinelibrary.wiley.com/journal/9575

About the journal